Korean Journal of Veterinary Service (한국동물위생학회지)

The Korean Society of Veterinary Service (한국동물위생학회)
권호 표지
DOI QR코드

DOI QR Code

Cystatin C for managing diuretic-induced kidney dysfunction in MMVD dogs

  • Donghyun Han (Choi Youngmin Animal Medical Center) ;
  • Jae Hyeon Cho (Institute of Animal Medicine, Gyeongsang National University) ;
  • Chung Hui Kim (Institute of Animal Medicine, Gyeongsang National University)
  • Received : 2023.06.02
  • Accepted : 2023.08.02
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cystatin C, a low-molecular-weight protein synthesized by cells, is being explored as a valuable biomarker for assessing renal function in veterinary medicine. Although the relationship between cystatin C and heart disease remains unclear, some studies suggest a possible association. This retrospective case-control study aimed to investigate the role of cystatin C as a biomarker for heart disease and its correlation with diuretic use in veterinary clinical practice. A total of 39 dogs were included in this study, comprising 9 control dogs without a predisposition to heart disease and 30 dogs in the study group diagnosed with heart disease. Among the 30 dogs with heart disease, 18 exhibited symptoms indicative of heart failure. Results showed significantly higher cystatin C levels in the heart disease group compared to the control group (P<0.05). However, no significant differences were observed among different stages of heart disease severity in the control group. Furthermore, cystatin-C showed statistically positive correlations with BUN (r=0.478, P<0.01), creatinine (r=0.506, P<0.01), and furosemide (r=0.338, P<0.05). Diuretics are essential for managing congestive heart failure, and the observed associations between cystatin C and furosemide suggest potential impacts of diuretic use on renal function in dogs with heart failure. Monitoring renal function markers, such as cystatin C, can aid in predicting and managing potential renal complications, ultimately improving the overall health and quality of life of dogs with heart disease.

Keywords

References

  1. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. 1990. Structure and expression of the human cystatin C gene. Biochem J 268: 287-294. https://doi.org/10.1042/bj2680287
  2. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V, Stepien R. 2009. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 23: 1142-1150. https://doi.org/10.1111/j.1939-1676.2009.0392.x
  3. Atkins CE, Haggstrom J. 2012. Pharmacologic management of myxomatous mitral valve disease in dogs. J Vet Cardiol 14: 165-184. https://doi.org/10.1016/j.jvc.2012.02.002
  4. Brown S, Atkins C, Bagley R, Carr A, Cowgill L, Davidson M, Egner B, Elliott J, Henik R, Labato M, Littman M, Polzin D, Ross L, Snyder P, Stepien R. 2007. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med 21: 542-558. https://doi.org/10.1111/j.1939-1676.2007.tb03005.x
  5. Brown S, Elliott J, Francey T, Polzin D, Vaden S. 2013. Consensus recommendations for standard therapy of glomerular disease in dogs. J Vet Intern Med 27 (Suppl 1): S27-43. https://doi.org/10.1111/jvim.12230
  6. Brown S. 2013. Introduction from the International Renal Interest Society. J Vet Intern Med 27 (Suppl 1): S1.
  7. Currie G, Delles C. 2013. Proteinuria and its relation to cardiovascular disease. International journal of nephrology and renovascular disease. Int J Nephrol Renovasc Dis 21: 13-24. https://doi.org/10.2147/IJNRD.S40522
  8. Dharnidharka VR, Kwon C, Stevens G. 2002. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40: 221-226. https://doi.org/10.1053/ajkd.2002.34487
  9. Drum MG, Marcellin-Little DJ, Davis MS. 2015. Principles and applications of therapeutic exercises for small animals. Vet Clin North Am Small Anim Pract 45: 73-90. https://doi.org/10.1016/j.cvsm.2014.09.005
  10. Ellison DH. 2001. Diuretic therapy and resistance in congestive heart failure. Cardiology 96: 132-143. https://doi.org/10.1159/000047397
  11. Elmahdy MF, Allehyani NM, Shehata NM, Alanazi MO. 2021. Diuretics increase Blood Creatinine in the Treatment of Hypertension. Medico-Legal Update 21: 780-785. https://doi.org/10.37506/mlu.v21i2.2777
  12. Felker GM. 2012. Loop diuretics in heart failure. Heart Fail Rev 17: 305-311. https://doi.org/10.1007/s10741-011-9245-3
  13. Ghys L, Paepe D, Smets P, Lefebvre H, Delanghe J, Daminet S. 2014. Cystatin C: a new renal marker and its potential use in small animal medicine. J Vet Intern Med 28: 1152-1164. https://doi.org/10.1111/jvim.12366
  14. Hall J, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell D. 2016. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. J Vet Intern Med 30: 794-802. https://doi.org/10.1111/jvim.13942
  15. Hall J, Yerramilli M, Obare E, Yerramilli M, Jewell D. 2014. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med 28: 1676-1683. https://doi.org/10.1111/jvim.12445
  16. Hansson K, Haggstrom J, Kvart C, Lord P. 2002. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 43: 568-575. https://doi.org/10.1111/j.1740-8261.2002.tb01051.x
  17. Herget-Rosenthal S, Bokenkamp A, Hofmann W. 2007. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 40: 153-161. https://doi.org/10.1016/j.clinbiochem.2006.10.014
  18. Huerta A, Lopez B, Ravassa S, San Jose G, Querejeta R, Beloqui O, Zubillaga E, Rabago G, Brugnolaro C, Diez J, Gonzalez A. 2016. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. J Hypertens 34: 130-138. https://doi.org/10.1097/HJH.0000000000000757
  19. Iwasa N, Takashima S, Iwasa T, Iwasa K, Suzuki T, Kobatake Y, Kitagawa H, Nishii N. 2018. Serum cystatin C concentration measured routinely is a prognostic marker for renal disease in dogs. Res Vet Sci 119: 122-126. https://doi.org/10.1016/j.rvsc.2018.06.014
  20. Keene BW, Atkins CE, Bonagura JD, Fox PR, Haggstrom J, Fuentes VL, yama MA, Rush JE, Stepien R, Uechi M. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 33: 1127-1140. https://doi.org/10.1111/jvim.15488
  21. Koenig W, Twardella D, Brenner H, Rothenbacher D. 2005. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51: 321-327. https://doi.org/10.1373/clinchem.2004.041889
  22. Laterza OF, Price CP, Scott MG. 2002. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48: 699-707. https://doi.org/10.1093/clinchem/48.5.699
  23. Liang KV, Williams AW, Greene EL, Redfield MM. 2008. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 36 (Suppl 1): S75-88. https://doi.org/10.1097/01.CCM.0000296270.41256.5C
  24. Luo J, Wang LP, Hu HF, Zhang L, Li YL, Ai LM, Mu HY, Wang K. 2015. Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta-analysis. Clin Chim Acta 450: 39-45. https://doi.org/10.1016/j.cca.2015.07.016
  25. Martinelli E, Crosara S, Locatelli C, Zanaboni AM, Brambilla P, Quintavalla C. 2020. Prospective evaluation of renal function in dogs with chronic mitral valve disease. bioRxiv: 2020.2003.2018.996785.
  26. Miyagawa Y, Takemura N, Hirose H. 2009. Evaluation of the measurement of serum cystatin C by an enzyme-linked immunosorbent assay for humans as a marker of the glomerular filtration rate in dogs. J Vet Med Sci 71: 1169-1176. https://doi.org/10.1292/jvms.71.1169
  27. Morgan KRS, Monteith G, Raheb S, Colpitts M, Fonfara S. 2020. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation. Vet J 263: 105518.
  28. Nabity M, Lees G, Boggess M, Yerramilli M, Obare E, Yerramilli M, Rakitin A, Aguiar J, Relford R. 2015. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney disease in dogs. J Vet Intern Med 29: 1036-1044.
  29. Oh SW, Han SY. 2015. Loop diuretics in clinical practice. Electrolyte Blood Press 13: 17-21. https://doi.org/10.5049/EBP.2015.13.1.17
  30. Pouchelon JL, Atkins CE, Bussadori C, Oyama MA, Vaden SL, Bonagura JD, Chetboul V, Cowgill LD, Elliot J, Francey T, Grauer GF, Fuentes VL, Moise NS, Polzin DJ, Dongen AMV, Israel NV. 2015. Cardiovascular-renal axis disorders in the domestic dog and cat: a veterinary consensus statement. J Small Anim Pract 56: 537-552. https://doi.org/10.1111/jsap.12387
  31. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. 2008. Cardiorenal syndrome. J Am Coll Cardiol 52: 1527-1539. https://doi.org/10.1016/j.jacc.2008.07.051
  32. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ. 2009. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 204: 298-303. https://doi.org/10.1016/j.atherosclerosis.2008.08.016
  33. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. 2005. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-2060. https://doi.org/10.1056/NEJMoa043161
  34. Society IRI. 2023. IRIS staging of CKD. http://www.iriskidney.com.
  35. Zhao R, Li Y, Dai W. 2016. Serum Cystatin C and the risk of coronary heart disease in ethnic Chinese patients with normal renal function. Lab Med 47: 13-19.  https://doi.org/10.1093/labmed/lmv004